Synonym
Meloxicam; Mobic; Mobicox; Movalis; Meloxicamum; Uticox; Parocin; reumoxicam; Movicox;
IUPAC/Chemical Name
(E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2H-benzo[e][1,2]thiazin-4(3H)-one 1,1-dioxide
InChi Key
DWMREKMVXIFPFM-ACCUITESSA-N
InChi Code
InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,19H,1-2H3,(H,15,16)/b13-11+
SMILES Code
CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Meloxicam is a non-steroidal antiinflammatory agent, inhibits COX activity, with IC50s of 0.49 µM and 36.6 µM for COX-2 and COX-1, respectively.
In vitro activity:
In the current study, the in vitro effects of low-dose meloxicam (0.25 µg/ml) on CF41.Mg canine mammary carcinoma cells were evaluated. Cell migration and invasion were significantly reduced following treatment with meloxicam. These results indicate that 0.25 µg/ml meloxicam reduces cell migration and invasion, in part through modulating MMP-2 and β-catenin expression.
Reference: Oncol Lett. 2017 Aug;14(2):2198-2206.
In vivo activity:
In a 2-period cross-over study, synovitis was induced at T = 0 h in the L or R intercarpal joint of 6 horses by intraarticular injection of 0.5 ng lipopolysaccharide (LPS). Horses received once daily meloxicam (0.6 mg/kg bwt per os) or placebo starting at post injection hour (PIH) 2, and clinical evaluations as well as blood and synovial fluid (SF) sampling were performed at PIH 0, 8, 24 and 168. Meloxicam caused a significant reduction in lameness at PIH 8 and 24 and tended to reduce effusion. In addition, meloxicam significantly suppressed SF prostaglandin E2 and substance P release at PIH 8 and bradykinin at PIH 24 compared to placebo treatment.
Reference: Equine Vet J. 2009 Sep;41(7):693-9. https://pubmed.ncbi.nlm.nih.gov/19927589/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMF |
20.0 |
56.92 |
| DMSO |
33.3 |
94.86 |
| DMSO:PBS (pH 7.2) (1:1) |
0.5 |
1.42 |
| Water |
0.7 |
1.91 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
351.40
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Iturriaga MP, Paredes R, Arias JI, Torres CG. Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells. Oncol Lett. 2017 Aug;14(2):2198-2206. doi: 10.3892/ol.2017.6400. Epub 2017 Jun 16. PMID: 28781660; PMCID: PMC5530185.
2. Naruse T, Nishida Y, Hosono K, Ishiguro N. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis. 2006 Mar;27(3):584-92. doi: 10.1093/carcin/bgi240. Epub 2005 Oct 11. PMID: 16219634.
3. de Grauw JC, van de Lest CH, Brama PA, Rambags BP, van Weeren PR. In vivo effects of meloxicam on inflammatory mediators, MMP activity and cartilage biomarkers in equine joints with acute synovitis. Equine Vet J. 2009 Sep;41(7):693-9. doi: 10.2746/042516409x436286. PMID: 19927589.
4. Jones CJ, Streppa HK, Harmon BG, Budsberg SC. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs. Am J Vet Res. 2002 Nov;63(11):1527-31. doi: 10.2460/ajvr.2002.63.1527. PMID: 12428662.
In vitro protocol:
1. Iturriaga MP, Paredes R, Arias JI, Torres CG. Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells. Oncol Lett. 2017 Aug;14(2):2198-2206. doi: 10.3892/ol.2017.6400. Epub 2017 Jun 16. PMID: 28781660; PMCID: PMC5530185.
2. Naruse T, Nishida Y, Hosono K, Ishiguro N. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis. 2006 Mar;27(3):584-92. doi: 10.1093/carcin/bgi240. Epub 2005 Oct 11. PMID: 16219634.
In vivo protocol:
1. de Grauw JC, van de Lest CH, Brama PA, Rambags BP, van Weeren PR. In vivo effects of meloxicam on inflammatory mediators, MMP activity and cartilage biomarkers in equine joints with acute synovitis. Equine Vet J. 2009 Sep;41(7):693-9. doi: 10.2746/042516409x436286. PMID: 19927589.
2. Jones CJ, Streppa HK, Harmon BG, Budsberg SC. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs. Am J Vet Res. 2002 Nov;63(11):1527-31. doi: 10.2460/ajvr.2002.63.1527. PMID: 12428662.
1: Low-dose meloxicam (Vivlodex) for osteoarthritis pain. Med Lett Drugs Ther. 2016 Mar 14;58(1490):35-6. PubMed PMID: 26963155.
2: Almukainzi M, Jamali F, Aghazadeh-Habashi A, Löbenberg R. Disease specific modeling: Simulation of the pharmacokinetics of meloxicam and ibuprofen in disease state vs. healthy conditions. Eur J Pharm Biopharm. 2016 Mar;100:77-84. doi: 10.1016/j.ejpb.2015.12.004. Epub 2016 Jan 2. PubMed PMID: 26752427.
3: Alomrani AH, Badran MM. Flexosomes for transdermal delivery of meloxicam: characterization and antiinflammatory activity. Artif Cells Nanomed Biotechnol. 2016 Feb 28:1-8. [Epub ahead of print] PubMed PMID: 26924417.
4: Takami Y, Eguchi S, Tateishi M, Ryu T, Mikagi K, Wada Y, Saitsu H. A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment. Hepatol Int. 2016 Feb 4. [Epub ahead of print] PubMed PMID: 26846471.
5: Ianiski FR, Alves CB, Ferreira CF, Rech VC, Savegnago L, Wilhelm EA, Luchese C. Meloxicam-loaded nanocapsules as an alternative to improve memory decline in an Alzheimer's disease model in mice: involvement of Na(+), K(+)-ATPase. Metab Brain Dis. 2016 Feb 27. [Epub ahead of print] PubMed PMID: 26922073.
